NLRP3 and obesity disorder: Of note, in IEC‐6 cells, the incubation with IL‐1β receptor antagonist, anakinra, in the presence of the conditioned medium derived from cocultured EGCs, previously treated with PA and LPS, counteracted the reduction of ZO‐1 and occludin as well as the increase in FITC‐dextran flux (Figure 7B–G), thus highlighting the involvement of enteric glial NLRP3‐mediated IL‐1β release in the mucosal barrier dysfunctions associated with obesity.